DEERFIELD, Ill., May 04, 2023 (GLOBE NEWSWIRE) -- Surgalign Holdings, Inc., (NASDAQ: SRGA) a global medical technology company focused on…
Reached agreement with FDA on confirmatory Phase 3 clinical trial design in 408 subjects with primary endpoint of all-cause mortality…
Reports record revenue of $15.5 million for the first-quarter quarter of 2023GAAP diluted EPS of $0.27 and non-GAAP diluted EPS…
BRISBANE, Calif., May 04, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing…
Q1 2023 total revenues of $95.3 million, compared to $35.0 million in the same period in 2022 CAPLYTA Q1 2023…
- Phase 3 ATTRibute-CM registrational trial of acoramidis for transthyretin amyloid cardiomyopathy (ATTR-CM) has now completed last patient last visit…
NEW YORK, May 04, 2023 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced…
Additional AB-729 off-treatment data highlighted in an oral presentation at the Global Hepatitis Summit 2023 Dosed first subject in Phase…
Leading physicians from Cleveland Clinic to present data from three posters that showcase the Company’s novel PURE EP™ PlatformWestport, CT,…
95% success rate of reaching pre-determined vascular target with no intraoperative complications presented during pre-clinical studiesHINGHAM, Mass., May 03, 2023…